LEXINGTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020.

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 - LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quarter 2020 and provided a corporate update.

Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020 Data from studies of KB39 and KB174 to be presented at The Liver Meeting ® 2020 , the AASLD Annual Meeting LEXINGTON, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kaleido

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease.

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed President and

Top-line safety, tolerability and activity results expected in mid-2021 LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that the first patient has been dosed in its clinical study evaluating Microbiome Metabolic Therapy (MMT™) candidate

LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic encephalopathy (HE) will be featured during The Digital International Liver Congress™, the Annual Meeting of

LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, will

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 -   LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc.

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass. , July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting